Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Study helps solve the puzzle of checkpoint inhibitor myocarditis
  • News

Study helps solve the puzzle of checkpoint inhibitor myocarditis

  • 22 November 2024
  • Janet Fricker
Study helps solve the puzzle of checkpoint inhibitor myocarditis
Total
0
Shares
0
0
0
0
0

The immune reaction that occurs in the hearts of patients taking checkpoint inhibitors who develop immune checkpoint myocarditis may be distinct from the immune responses occurring in the tumours of these patients. The study, published in in Nature, 6 November, identifies cytotoxic T cells, dendritic cells, and inflammatory fibroblasts as the likely mediators of the cardiac pathology.

“Our results provide a more detailed picture of what’s happening in the heart and suggest intriguing new ways forward to improve patient care,” says co-senior author Alexandra-Chloe Villani, from Massachusetts General Hospital (MGH) and Broad Institute of MIT and Harvard. The study, she adds, is the first to rigorously examine the intracardiac biology of human checkpoint inhibitor myocarditis across heart, blood and tumour tissue compartments.

Approximately one-third of patients with cancer in the US are eligible to receive immune checkpoint inhibitors (ICIs). Most patients receiving these drugs develop at least one type of toxicity, with 10–50% developing a severe complication. Arguably, the most severe is checkpoint myocarditis, which occurs in approximately 1% of patients treated with immune checkpoint inhibitors. Despite corticosteroid treatment, the incidence of major adverse cardiac events in ICI-associated myocarditis remains high, ranging from 25 to 50%.

For the current study, the investigators obtained heart, blood and tumour samples from 28 patients with ICI-associated myocarditis and from 41 non-myocarditis controls. The heart samples were obtained either during clinically-indicated endomyocardial biopsy procedures or from autopsies conducted within the first six hours after death. A variety of tools were then used to analyse samples, including single cell RNA sequencing (scRNA-seq), T-cell receptor sequencing (TCR-seq), circulating protein immunoassays, microscopy, and T-cell receptor functional assays.

The main findings  of the study included:

  • Increased frequencies and co-localisation of cytotoxic T cells, conventional dendritic cells, and inflammatory fibroblasts in immune-related myocarditis heart tissue.
  • Decreased frequencies of plasmacytoid dendritic cells, conventional dendritic cells, and B-lineage cells, but an increased frequency of other mononuclear phagocytes in the blood of immune-related myocarditis patients.
  • The presence of heart-expanded T cell clones in a population of cycling CD8 T cells in the blood being associated with fatal immune-related myocarditis case status.

“Until now, a role for T cells and macrophages was hypothesised based on descriptive histopathologic studies. The more detailed investigations in our paper now nominate cytotoxic T cells, dendritic cells, and inflammatory fibroblasts as likely cellular mediators of the observed cardiac pathology in ICI myocarditis,” co-first author and oncologist Steve Blum, from MGH and the Broad Institute, tells Cancerworld. “We hypothesise that these three populations are part of an inflammatory cascade that is triggered by the use of ICI drugs, though why this occurs in only approximately 1% of ICI recipients remains elusive.”

An additional finding was that T cell clones enriched in heart tissue were largely distinct from those enriched in paired tumour tissue. “These nonoverlapping repertoires argue against a model of ICI-associated myocarditis in which the T-cell responses in the heart and tumour are directed against a common antigen in at least a large fraction of patients. The finding additionally supports efforts to identify therapies that can attenuate cardiac inflammation while preserving anti-tumour immunity,” says co-first author Daniel Zlotoff, a cardiologist at MGH and the Broad Institute.

Furthermore, across 52 T cell clones derived from eight patients, the team did not identify any that recognised the putative cardiac autoantigens α-myosin, troponin I, or troponin T. A prior publication had suggested that T cells specific for α-myosin were drivers of ICI myocarditis pathophysiology. “While we cannot exclude the possibility that infrequent heart T cell clones may recognize α-myosin, our findings suggest that the most abundant clones recognise another antigen,” says co-senior author and MGH oncologist Kerry Reynolds.

Going forward, the team are looking to identify the antigens in the heart targeted by the cardiac T cells in ICI myocarditis. “Further investigation of immunologically active factors in the blood of ICI myocarditis patients could lead to identification of circulating biomarkers that would increase our ability to risk-stratify, diagnose, and treat these patients,” says Villani.

Already, findings from the current study have been used to support the phase 3 ATRIUM (AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis) trial (NCT05335928), which is investigating use of abatacept in 390 patients with ICI-associated myocarditis enrolled across 48 sites. The primary outcome of the study, which started enrolling patients in June 2022 and is led by Tomas Neilan and Paul Ridker, is to assess the reduction in major adverse cardiac events (including cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyarrhythmia, or incident heart failure). “Abatacept inhibits T cell activation by binding to CD80 and CD86, thereby blocking their interaction with the CD28 co-stimulatory receptor,” explains Neilan. “Our study showed that these pathways are activated in ICI myocarditis and that targeting these pathways appears logical.”

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • ATRIUM study
  • cardiac
  • immune checkpoint inhibitors
  • immune reaction
  • immunotherapy
  • myocarditis
  • side effect
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • ESCO Contest

Advocacy in oncology: Fighting for patients inside and outside the hospital

  • 21 November 2024
  • Kleida Mati*
View Post
Next Article
  • Policy

Florida shows cancer outcomes are better where healthcare reflects local cultures

  • 22 November 2024
  • Myriam Vidal Valero
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.